BIO Double Helix Sponsor
Sponsors

Company Profile

Kereos, Inc.

Cancer
Cardiovascular Disease

4041 Forest Park Avenue
Saint Louis, MO 63108
USA
www.kereos.com 		Incorporated in 1999
19 Employees 		Privately Held

This Year's Highlights

  • Kereos has advanced lead candidate KI-0001 for cancer imaging into final stages of pre-IND testing.
  • In September 2006, Kereos announced the publication of a preclinical study showing the ability of Kereos's technology to detect and treat atherosclerotic plaque, a primary cause of heart attack and stroke.
  • Kereos and its collaborators at Washington University were selected by the NCI for funding as one of eight Cancer Centers of Nanotechnology Excellence.

Anticipated Highlights

  • Kereos is preparing to enter the clinic with lead candidate KI-0001 in the first quarter of 2008.
  • Additional significant partnerships in both cancer and cardiovascular disease are expected in the next 12 months.
  • Independently and with its partners, Kereos will continue to advance its pipeline of products.

Corporate Mission

Every year, more than two million people die in the United States alone from cancer and cardiovascular disease. Despite a nearly $130 billion price tag for treatment, mortality and morbidity in both diseases remain high. Kereos, Inc. develops targeted imaging agents and therapeutics to better detect and treat these top two killers. Our ligand-targeted technologies are designed to solve urgent, unmet medical needs by enabling diagnosis, assessment, and monitoring of otherwise undetectable life-threatening disease and more effective, targeted delivery of therapeutics. With an experienced drug development team and strong partners, Kereos is committed to developing its pipeline of products.